Ruxolitinib resistance or intolerance in steroid‐refractory acute graft‐<i>versus</i>‐host disease — a real‐world outcomes analysis
Sameem Abedin, Nahid Rashid, Mark A. Schroeder, Rizwan Romee, Mary Nauffal, Muhamad Alhaj Moustafa, Mohamed A. Kharfan‐Dabaja, Jeanne Palmer, William J. Hogan, Mehrdad Hefazi, Samantha Larson, Shernan G. Holtan, Zachariah DeFilipp, Reena Jayani, Bhagirathbhai Dholaria, Joseph Pidala, Farhad Khimani, Michael R. Grunwald, Candace Butler, Mehdi Hamadani
Abstract
Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.